The Anti-Aging Pill for Dogs Is Almost Here. The FDA Is Already On Board.

Every dog owner knows how the story ends. You know it from the beginning — from the moment that puppy looks up at you. What you don't know is how much time you have, or whether the last years will be good ones.

A San Francisco biotech called Loyal has spent six years trying to change that math. They're now closer than anyone has ever been.

What LOY-002 Actually Is

LOY-002 is a daily prescription pill for senior dogs — currently targeting dogs 10 years and older, weighing at least 14 lbs. It works as a caloric restriction mimetic: it delivers the biological benefits of a severely reduced-calorie diet — better metabolic function, reduced age-related disease burden — without actually cutting food intake or causing weight loss.

The science is grounded in a landmark Purina study that found calorie-restricted dogs lived roughly two years longer on average than their littermates, with delayed onset of cancer and osteoarthritis. LOY-002 aims to capture those gains without the hardship of actual caloric restriction.

"Part of the genius of LOY-002 is that it achieves some of the same goals biologically as caloric restriction without the hardship and the risks," said Dr. Brennen McKenzie, Loyal's Director of Veterinary Medicine. "It doesn't require restricting calories, and it doesn't cause them to lose weight."

The FDA Pathway — Where It Stands Right Now

Loyal is pursuing conditional FDA approval — a pathway designed for drugs that have demonstrated safety and reasonable expectation of efficacy, but whose full long-term study isn't yet complete. Three major technical acceptances are required:

✅ Reasonable Expectation of Efficacy — FDA's formal acceptance that the drug can plausibly extend canine lifespan. Loyal has earned this twice over. ✅ Target Animal Safety — FDA acceptance of the safety data package, cleared January 2026. 🔄 Manufacturing — the final requirement before conditional approval. In progress.

If manufacturing acceptance comes through, Loyal could reach the market with the first FDA-approved longevity drug for any species in history — including humans.

"If we get approval for this drug, it'll be the first time any aging drug, any lifespan drug, has been approved for any species," McKenzie told Fortune. "I hope it'll open some doors scientifically."

The Largest Clinical Trial in Veterinary History

Alongside the regulatory process, Loyal is running the STAY study — 1,300 dogs across 72 veterinary clinics, randomized, double-blinded, placebo-controlled. When they announced they'd try to enroll 1,000 dogs, scientists said it was impossible. Over 12,000 people emailed wanting to participate.

That number tells you everything about where dog owners are emotionally on this.

The study will run a minimum of four years — but LOY-002 could reach the market through conditional approval before the study concludes. The FDA built this mechanism specifically so promising, safe drugs don't have to wait a decade.

How Much Time Could It Add?

McKenzie was careful here: "Numbers are always tricky, because we tend to fixate on them and think they're more reliable than they are."

The STAY study was designed to detect at least a one-year difference. The Purina precedent suggests two years is possible. But the honest framing — until the study concludes — is: meaningfully more time, with better quality.

LOY-002 targets the metabolic dysfunction that underlies arthritis, cancer, and cognitive decline simultaneously, rather than treating each condition as it appears. That upstream approach is the real story.

The Broader Implication

Loyal has raised over $150 million since founding in 2019, including a $100M round earlier this year. CEO Celine Halioua has been direct: if a longevity drug can be proven in dogs — a species that shares our environments, our diseases, and our aging patterns — it changes what's believed to be possible for human medicine too.

This isn't just a pet health story. It's a proof-of-concept for longevity science at scale.

What This Means If Your Dog Is Getting Older

There is no approved longevity drug for dogs yet. But the finish line is in sight — and the FDA's formal sign-offs are unprecedented.

Your vet may already know about the STAY study given its reach across 72 clinics. Worth asking.

And while you wait: weight management, anti-inflammatory nutrition, and regular vet checkups all act on the same metabolic pathways LOY-002 targets. You don't have to wait for a pill to start protecting the years you have.

Watch this space. The manufacturing acceptance could come any time.

This is not veterinary advice. Speak with a licensed veterinarian about any health or longevity plan for your dog.